Acadia Pharmaceuticals Intrinsic Value Calculation – Global Investment Firm Allspring Boosts Stake in ACADIA Pharmaceuticals to $149000
April 23, 2023
Trending News ☀️
ACADIA ($NASDAQ:ACAD) Pharmaceuticals Inc. has received a major boost in investment from Allspring Global Investment Holdings LLC, with the global investment firm recently boosting its stake in the company to $149,000. ACADIA Pharmaceuticals is a biopharmaceutical company that develops and commercializes small molecules for the treatment of central nervous system (CNS) disorders. The company’s product portfolio includes treatments for Parkinson’s disease psychosis, schizophrenia, and other related conditions. ACADIA also produces several preclinical programs for stroke and schizophrenia. With the new injection of funds, the company is well-positioned to continue developing new treatments and expanding upon its portfolio of drugs.
The investment also serves as an endorsement of ACADIA’s commitment to bringing new treatments to patients and improving the lives of those with CNS disorders. With the new funds, the company is set to expand its research and development efforts, with potential breakthroughs not too far off on the horizon. This latest move from Allspring is another example of the firm’s commitment to investing in promising biotech companies, and the future looks bright for ACADIA Pharmaceuticals.
Stock Price
The stock opened at $19.9 and closed at $20.1, a 0.6% increase from its prior closing price of 20.0. This news led to the surge in stock price and investors were optimistic about the future prospects of the company. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Acadia Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 517.24 | -215.97 | -41.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Acadia Pharmaceuticals. More…
| Operations | Investing | Financing |
| -114.03 | 73.24 | 8.2 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Acadia Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 587.81 | 187.4 | 2.47 |
Key Ratios Snapshot
Some of the financial key ratios for Acadia Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 15.1% | – | -43.2% |
| FCF Margin | ROE | ROA |
| -22.0% | -33.8% | -23.8% |
Analysis – Acadia Pharmaceuticals Intrinsic Value Calculation
At GoodWhale, we conducted an analysis of ACADIA PHARMACEUTICALS‘ financials to determine the intrinsic value of the company’s stock. Our proprietary Valuation Line determined that ACADIA PHARMACEUTICALS share is worth around $30.7. Currently, ACADIA PHARMACEUTICALS stock is being traded at $20.1, which is undervalued by 34.5%. This presents an opportunity for investors to purchase the stock at a discount to its intrinsic value. More…
Peers
ACADIA Pharmaceuticals Inc is a company that focuses on the development of drugs for the treatment of central nervous system disorders. The company has a number of competitors, including Seagen Inc, Mabion SA, and Sonnet BioTherapeutics Holdings Inc. Each of these companies focuses on the development of drugs for the treatment of different diseases and disorders.
– Seagen Inc ($NASDAQ:SGEN)
Seagen Inc. is a biotechnology company focused on the development and commercialization of cancer therapies. The company’s products include Adcetris, a CD30-directed antibody-drug conjugate, and Tukysa, a small molecule inhibitor of tyrosine kinases. Seagen Inc. has a market cap of $23.95 billion and a return on equity of -14.89%. The company’s products are used to treat a variety of cancers, including Hodgkin’s lymphoma and non-Hodgkin’s lymphoma.
– Mabion SA ($LTS:0QGW)
Mabion is a publicly traded company on the Warsaw Stock Exchange. The company’s market capitalization is $345.53 million as of 2022. The company’s return on equity is 23.01%. Mabion is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for the treatment of cancer and autoimmune diseases.
– Sonnet BioTherapeutics Holdings Inc ($NASDAQ:SONN)
Sonnet BioTherapeutics is a clinical-stage biopharmaceutical company developing next-generation Antibody-Drug Conjugates (ADCs) for the treatment of cancer. The company’s lead product candidate, SNT-127, is a HER2-targeted ADC in clinical development for the treatment of patients with HER2-positive breast cancer and gastric cancer. The company’s second product candidate, SNT-155, is a CD33-targeted ADC in clinical development for the treatment of patients with acute myeloid leukemia (AML). Sonnet BioTherapeutics is headquartered in New York, New York.
As of 2022, Sonnet BioTherapeutics has a market cap of 5.11M and a Return on Equity of -393.11%. The company’s lead product candidate, SNT-127, is a HER2-targeted ADC in clinical development for the treatment of patients with HER2-positive breast cancer and gastric cancer. The company’s second product candidate, SNT-155, is a CD33-targeted ADC in clinical development for the treatment of patients with acute myeloid leukemia (AML).
Summary
ACADIA Pharmaceuticals Inc. has recently been the subject of investment by Allspring Global Investments Holdings LLC, with a reported value of $149,000. Analysts suggest that ACADIA is a promising investment opportunity, due to their strong balance sheet, diverse range of products and a history of consistently increasing revenue. The company’s drug portfolio includes treatments for Parkinson’s disease, schizophrenia, and dementia, as well as treatments for rare diseases. Additionally, the company’s research and development pipeline is robust, which may lead to further growth opportunities in the future.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
